[1, 2, 3, 4]. CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure), GISSI-HF, 10 [5, 6, 7]. 1-

. , 2'2010


87

```
III–IV
            50
                                                        ( ,
NYHA).
                         ( ) <35%)
                                           6
                                      ,
1
                     5-10 ,
                     2,5
                                                     5-10
12,5
                                                5
6-
( -1)
                                               1.
               −6 ( −6),
           - 1).
3,5 MHz «ULTIMA PRO–30» («
                                                      ).
            Statistica for Windows 6.0.
(
(50–
                                                       ).
                                                 2
     48
               - 23
                                          25 -
         ( )
                                          ( ),
                   41,5%
```

88 . , 2'2010


```
( . 1).
(<100 / ) 1
5 (20%), 5
                                    - 24 (96%)       ( . 1).
       175 ¶153,2
                             144,8
                    143,4
       125 145,7
       100 •
                                                       89,6*
       50
                              2
                                                         5
                                 (100 / )
                                                      (*- <0,05)
     1 –
                    16%.
                                                 12% ( 39,5 /
44,2 / ) ( <0,05),
                                                    2% ( >0,05).
                                         <39 / ),
                                                        ( . 2).
                                                         5 .)
                                                          71,6
86,7 / ,
                                              13,2 /
                                                          11,5 /
            68,5 /
                       110,5 / ,
14,6 /
            9,8 /
                                       22,3%,
61,3%,
                                                         12,9% 32,9%.
                                                         ( <0,05).
                                                                  89
```

, 2'2010



2 –

. 3.



→ Группа статина

•••• Группа сравнения

* _


(*- <0,05; **- <0,01)

3 –

```
80%, 89%, 94,1% 94,4%
                                                     (p<0,01
         ).
                                                                34,1%
                   27,3% (p<0,05), -6 - 42,3% (p<0,01)
(p<0,01), -1 -
                          −8 36,9% (p>0,05).
                                                                - 1
23,8% (p<0,05).
                                        (IV
        III, IV
                                             ( <0,01).
                                              3
        3, II – 1
15
                               I - 3
                                                                III
III
                          8,
                          III
                                               3,
                                 II
        IV
8
                 III
                                                             5
                                           40 / .
                                                                 S [8].
                       [9].
          [10].
                                                           N0-
(NOS)
                                                       [11,12].
          (4%)
```

. , 2'2010

91



1. 40
III IV 5
,
2. 40

SUMMARY

THE ROLE OF SIMVASTATINUM IN TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE AND CHRONIC HEART FAILURE

.N. Kochueva, G.I. Kochuev, A.S. Shalimova, V.G. Psareva, A.V. Linska

The article presents results of comparative study of efficiency of including of simvastatinum in the chart of treatment the patients with chronic heart failure of ischemic etiology and treatment without its use. More positive influence of chart of treatment with the use of simvastatinum to lipidal exchange, clinical state of the patients, global contractility of the left ventricle of heart, functional state of endothelium and whey concentrations of proinflammatory cytokines has been determined.

Key words: simvastatin, coronary heart disease, chronic heart failure.

- Statins in the treatment of chronic heart failure: A systematic review / P.Van der Harst, A.A. Voors, W.H. Van Gilst et al. // PLoS Med. – 2006. – Vol. 3, 8. – P. 1403–1413.
- 2. The relationship between cholesterol and survival in patients with chronic heart failure / M. Rauchhaus, A.L. Clark, W. Doehner et al. // J. Am. Coll. Cardiol. 2003. Vol. 43. P. 1933–1940.
- 4. Mungall M.M. Statin therapy in the elderly / M.M. Mungall, A. Gaw // Curr. Opin. Lipidol. 2004. Vol. 15. P. 453-457.

92 . , 2'2010

- 6. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of —3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure / L. Tavazzi, G. Tognoni, M.G. Franzosi et al. // Eur. J. Heart Fail. 2004. Vol. 6. P. 635–641.
- 7. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics / J. Kjekshus, P. Dunselman, M. Blideskog et al. // Eur. J. Heart Fail. 2005. Vol. 7. P. 1059–1069.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial // Lancet. – 2003. – Vol. 361. – P. 2005–2016.
- Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure / S.D. Katz, K. Hryniewicz, I. Hriljac et al. // Circulation. – 2005. – Vol. 111. – P. 310–314.
- 10. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide / A.Y. Chong, A.D. Blann, J. Patel et. al. // Circulation. 2004. Vol. 110. P.1794–1798.
- 11. Rikitake Y. Pases, statins, and nitric oxide / Y. Rikitake, J.K. Liao, G.T. Rho // Circ. Res. 2005. Vol. 97. P.1232–1235.
- Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins / F.W. Asselbergs, P. Van der Harst, G.A.J. Jessurun, R.A. Tio, W.H. Van Gilst // Vascul. Pharmacol. – 2005. – Vol. 42. – P.125–140.

12 2010 .

. , 2'2010 93